Protagonist Therapeutics, Inc. (PTGX)
NASDAQ: PTGX · Real-Time Price · USD
121.40
-2.62 (-2.11%)
Nov 20, 2026, 4:00 PM EST - Market closed
Protagonist Therapeutics Revenue
Protagonist Therapeutics had revenue of $274.41M in the quarter ending September 30, 2026, with 5,723.64% growth. This brings the company's total for the last twelve months to $551.69M, up 163.69% year-over-year. In the year 2025, Protagonist Therapeutics had annual revenue of $46.02M, down -89.41%. That makes Protagonist Therapeutics the 10,737th largest company in the world by revenue and 2,228th in the United States.
Revenue (ttm)
$551.69M
Revenue Growth
+163.69%
P/S Ratio
14.36
Revenue / Employee
$3,702,617
Employees
149
Market Cap
7.92B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 46.02M | -388.42M | -89.41% |
| Dec 31, 2024 | 434.43M | 374.43M | 624.06% |
| Dec 31, 2023 | 60.00M | 33.42M | 125.73% |
| Dec 31, 2022 | 26.58M | -776.00K | -2.84% |
| Dec 31, 2021 | 27.36M | -1.27M | -4.44% |
| Dec 31, 2020 | 28.63M | 28.40M | 12,293.07% |
| Dec 31, 2019 | 231.00K | -30.69M | -99.25% |
| Dec 31, 2018 | 30.93M | 10.86M | 54.14% |
| Dec 31, 2017 | 20.06M | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Madrigal Pharmaceuticals | 1.43B |
| Corcept Therapeutics | 963.65M |
| TG Therapeutics | 897.76M |
| Axsome Therapeutics | 865.27M |
| Twist Bioscience | 459.43M |
| Rhythm Pharmaceuticals | 280.75M |
| Cytokinetics | 113.29M |
| Praxis Precision Medicines | 7.46M |
PTGX News
- 5 days ago - Protagonist Therapeutics Transcript: Jefferies Global Healthcare Conference - Transcripts
- 11 days ago - Protagonist Therapeutics Transcript: 8th Annual Wolfe Research Healthcare Conference - Transcripts
- 12 days ago - Protagonist Therapeutics price target raised to $151 from $149 at JPMorgan - TheFly
- 12 days ago - Protagonist Therapeutics Slides: Corporate presentation - Filings
- 16 days ago - Protagonist Therapeutics reports Q3 EPS $3.07, consensus $2.66 - TheFly
- 16 days ago - Protagonist Therapeutics Earnings release: Q3 2026 - Filings
- 16 days ago - Protagonist Therapeutics Quarterly report: Q3 2026 - Filings
- 4 weeks ago - Protagonist Therapeutics price target raised to $160 from $155 at TD Cowen - TheFly